On May 19, 2020, Oragenics announced, that through its wholly-owned subsidiary, Noachis Terra, it has entered into an agreement with Aragen Bioscience, a leading contract research organization focused on accelerating pre-clinical biologics product development, to advance TerraCov2 the Companyﾒs SARS CoV-2 vaccine candidate.

Aragen will provide cell line development services to Oragenics to aid in the development of Oragenics’ TerraCoV2, which could provide specific immunity from the novel coronavirus (ﾓSARS-CoV-2ﾔ), the root cause of Coronavirus disease 2019.